Labetuzumab
Labetuzumab
Labetuzumab (pronounced la-be-tu-zu-mab) is a monoclonal antibody designed for the treatment of certain types of cancer. It is a biopharmaceutical product that is still in the experimental stages of development.
Etymology
The name "Labetuzumab" is derived from the International Nonproprietary Names (INN), where "zu" denotes humanized antibody, "tu" refers to the tumor, and "mab" is indicative of monoclonal antibody. The prefix "Labe" is likely related to the specific target or source of the antibody, but the exact origin is not publicly disclosed.
Mechanism of Action
Labetuzumab works by targeting the CEACAM5 antigen, a protein often found in high levels on the surface of cancer cells. By binding to this antigen, Labetuzumab can help the immune system recognize and destroy the cancer cells.
Clinical Trials
Labetuzumab has been studied in clinical trials for the treatment of colorectal cancer, pancreatic cancer, and other types of cancer. However, it is not yet approved by the FDA or other regulatory authorities.
Related Terms
- Monoclonal Antibodies
- CEACAM5
- Colorectal Cancer
- Pancreatic Cancer
- Biopharmaceutical
- Clinical Trials
- FDA
External links
- Medical encyclopedia article on Labetuzumab
- Wikipedia's article - Labetuzumab
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski